My Companies
Notification
Account
Log Out
Back

AstraZeneca Pharma India Secures CDSCO Approval for Benralizumab HES Indication

16 July 2026
Astrazeneca Pharma India Ltd.

AstraZeneca Pharma India received CDSCO approval to import and market Fasenra (benralizumab) for an additional indication: Hypereosinophilic Syndrome in patients aged 12 years and older, expanding the drug's label in India.

Recent Events

8 August 2026

AstraZeneca Pharma India Receives CDSCO Permission For Enhertu Breast Cancer Indication
28 July 2026

AstraZeneca Pharma India Secures CDSCO Nod For Enhertu Additional Breast Cancer Indication

Real time WhatsApp alerts using AI.

Get features of

  • Instant Notifications
  • Competitive Advantage
  • Critical Alerts
Signup or Sign in

Company Information